Full View

Low toxicity and excellent outcomes in patients with DLBCL without residual lymphoma at the time of CD19 CAR T-cell therapy

K Wudhikarn, AA Tomas, JR Flynn, SM Devlin… - Blood …, 2023 - ashpublications.org
CD19 chimeric antigen receptor (CAR) T-cell therapy represents a breakthrough for patients
with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL), inducing sustained …
被引用次数：26 相关文章

Low toxicity and excellent outcomes in patients with DLBCL without residual lymphoma at the time of CD19 CAR T-cell therapy

Cell Therapy Consortium - Blood Advances, 2023 - experts.umn.edu
CD19 chimeric antigen receptor (CAR) T-cell therapy represents a breakthrough for patients
with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL), inducing sustained …

Low toxicity and excellent outcomes in patients with DLBCL without residual lymphoma at the time of CD19 CAR T-cell therapy

Cell Therapy Consortium - Blood Advances, 2023 - mdanderson.elsevierpure.com
CD19 chimeric antigen receptor (CAR) T-cell therapy represents a breakthrough for patients
with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL), inducing sustained …
[HTML] sciencedirect.com

[HTML][HTML] Low toxicity and excellent outcomes in patients with DLBCL without residual lymphoma at the time of CD19 CAR T-cell therapy

K Wudhikarn, AA Tomas, JR Flynn, SM Devlin… - Blood Advances, 2023 - Elsevier
CD19 chimeric antigen receptor (CAR) T-cell therapy represents a breakthrough for patients
with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL), inducing sustained …

Low toxicity and excellent outcomes in patients with DLBCL without residual lymphoma at the time of CD19 CAR T-cell therapy

Cell Therapy Consortium - Blood Advances, 2023 - ohsu.elsevierpure.com
CD19 chimeric antigen receptor (CAR) T-cell therapy represents a breakthrough for patients
with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL), inducing sustained …
[HTML] nih.gov

[HTML][HTML] Low toxicity and excellent outcomes in patients with DLBCL without residual lymphoma at the time of CD19 CAR T-cell therapy

K Wudhikarn, AA Tomas, JR Flynn, SM Devlin… - Blood …, 2023 - ncbi.nlm.nih.gov
CD19 chimeric antigen receptor (CAR) T-cell therapy represents a breakthrough for patients
with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL), inducing sustained …

Low toxicity and excellent outcomes in patients with DLBCL without residual lymphoma at the time of CD19 CAR T-cell therapy

K Wudhikarn, AA Tomas, JR Flynn… - Blood …, 2023 - pubmed.ncbi.nlm.nih.gov
CD19 chimeric antigen receptor (CAR) T-cell therapy represents a breakthrough for patients
with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL), inducing sustained …

Low toxicity and excellent outcomes in patients with DLBCL without residual lymphoma at the time of CD19 CAR T-cell therapy.

K Wudhikarn, AA Tomas, JR Flynn, SM Devlin… - Blood …, 2023 - europepmc.org
CD19 chimeric antigen receptor (CAR) T-cell therapy represents a breakthrough for patients
with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL), inducing sustained …

Low toxicity and excellent outcomes in patients with DLBCL without residual lymphoma at the time of CD19 CAR T-cell therapy.

K Wudhikarn, JR Flynn, SM Devlin, J Brower… - Blood …, 2022 - europepmc.org
CD19 chimeric antigen receptor (CAR) T-cell therapy represents a breakthrough for patients
with relapsed/refractory (R/R) diffuse large B cell lymphoma (DLBCL) inducing sustained …